Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
“we think we'll have that fully enrolled and reading out late in 2027”
→ Read the source episode
Our resolution criterion
disputableAvalon Pharma publicly announces Phase 2 clinical trial data for APO2 program
More from The Long Run with Luke Timmerman
Matai Mammen predicts Parabolas will eventually conduct a basket trial using a genetic signature to enroll multiple tumor types responsive to zolucatotide
Matai Mammen predicts Parabolas will initiate Phase 3 trials for zolucatotide in desmoid tumors in H1 2027
Maize Therapeutics will determine within the next year whether its APOL1 and SLC6A19 programs pass phase two clinical trial scrutiny.
Maize Therapeutics will have initiated a pivotal study on APOL1 and advanced other programs through mid-stage development by August 2027.
Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.